Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (EW) from its SEC filings: 2025 revenue $6.1 billion (+12% vs the year before), net margin 18%, free cash flow $1.3 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Orthopedic, Prosthetic & Surgical Appliances & Supplies |
| Revenue (2025) | $6.1 billion |
| Revenue growth | +12% |
| Net income | $1.1 billion |
| Net margin | 17.7% |
| Free cash flow | $1.3 billion |
| Diluted EPS | $1.83 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +14% |
| Cash | $2.9 billion |
| Long-term debt | $598.7 million |
| Share count, 1 year | -2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.